Alumis Inc
NASDAQ:ALMS
Alumis Inc
Alumis Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2024-06-28. Alumis Inc. is a clinical-stage biopharmaceutical company. The company develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. The company builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. The company has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Alumis Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2024-06-28. Alumis Inc. is a clinical-stage biopharmaceutical company. The company develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. The company builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. The company has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
